Abstract:BackgroundThe innate immune response in the brain is initiated by pathogen-associated molecular patterns (PAMPS) or danger-associated molecular patterns (DAMPS) produced in response to central nervous system (CNS) infection or injury. These molecules activate members of the Toll-like receptor (TLR) family, of which TLR4 is the receptor for bacterial lipopolysaccharide (LPS). Although neurons have been reported to express TLR4, the function of TLR4 activation in neurons remains unknown.MethodsTLR4 mRNA expression in primary mouse glial and neuronal cultures was assessed by RT-PCR. Mouse mixed glial, neuronal or endothelial cell cultures were treated with LPS in the absence or the presence of a TLR4 specific antagonist (VIPER) or a specific JNK inhibitor (SP600125). Expression of inflammatory mediators was assayed by cytometric bead array (CBA) and ELISA. Activation of extracellular-signal regulated kinase 1/2 (ERK1/2), p38, c-Jun-N-terminal kinase (JNK) and c-Jun was assessed by Western blot. The effect of conditioned media of untreated- versus LPS-treated glial or neuronal cultures on endothelial activation was assessed by neutrophil transmigration assay, and immunocytochemistry and ELISA were used to measure expression of intercellular cell adhesion molecule (ICAM-1) and vascular cell adhesion molecule (VCAM-1).ResultsLPS induces strong release of the chemokines RANTES and CXCL1 (KC), tumor necrosis factor-α (TNFα) and IL-6 in primary mouse neuronal cultures. In contrast, LPS induced release of IL-1α, IL-1β and granulocyte-colony stimulating factor (G-CSF) in mixed glial, but not in neuronal cultures. LPS-induced neuronal KC expression and release were completely blocked by VIPER. In glial cultures, LPS induced activation of ERK1/2, p38 and JNK. In contrast, in neuronal cultures, LPS activated JNK but not ERK1/2 or p38, and the specific JNK inhibitor SP600125 significantly blocked LPS-induced KC expression and release. Finally, conditioned medium of LPS-treated neuronal cultures induced strong expression of ICAM-1 and VCAM-1 on endothelial cells, and induced infiltration of neutrophils across the endothelial monolayer, which was inhibited by VIPER.ConclusionThese data demonstrate for the first time that neurons can play a role as key sensors of infection to initiate CNS inflammation.

Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders

TLR4 Targeting as a Promising Therapeutic Strategy for Alzheimer Disease Treatment

Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems

Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease

Toll-like receptor 4: the potential therapeutic target for neuropathic pain]

Mechanistic insights on TLR-4 mediated inflammatory pathway in neurodegenerative diseases

T Cells Modulate the Microglial Response to Brain Ischemia

Toll‐like receptors in pathogenesis of neurodegenerative diseases and their therapeutic potential

Endogenous Ligands of TLR4 in Microglia: Potential Targets for Related Neurological Diseases

TLR-Mediated Signal Transduction and Neurodegenerative Disorders

The potential for treg-enhancing therapies in nervous system pathologies

Activation of Toll-like receptor 5 in microglia modulates their function and triggers neuronal injury

NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation

Toll-Like Receptors as Therapeutic Targets in Central Nervous System Tumors

Inhibition of TLR4 Induces M2 Microglial Polarization and Provides Neuroprotection via the NLRP3 Inflammasome in Alzheimer’s Disease

Toll-like receptor 4: A potential therapeutic target for multiple human diseases

TLR Signaling in Brain Immunity.

Toll-like receptor 4 contributes to poor outcome after intracerebral hemorrhage

Neuronal toll-like receptor 4 signaling induces brain endothelial activation and neutrophil transmigration in vitro

Toll-Like Receptors Mediate Opposing Dendritic Cell Effects on Treg/Th17 Balance in Mice With Intracerebral Hemorrhage

Targeting toll-like receptor-4 (TLR4)—an emerging therapeutic target for persistent pain states